New Drugs 2018 – Nurse Practitioner

  Price  $10.00

  Credits  2

Clear


Format
In 2018, the US Food and Drug Administration (FDA) approved 59 new drugs – the highest number in more than 10 years – including 19 first-in-class agents. Of the 59 new approvals, 73% received priority review. This issue of The Rx Consultant focuses on the new drugs that may be important additions (including a number of “firsts”) in their therapeutic areas: influenza infection, HIV-1 infection, pneumonia and skin infections, nonmetastatic, castration-resistant prostate cancer, endometriosis, migraine prophylaxis, moderate to severe acne, and chronic, idiopathic constipation. Dosing and drug interactions are detailed in Table 1. Brief descriptions of selected additional new drugs are shown in Table 2, and new HIV drugs and HIV drug combinations are decribed in Table 3. Table 4 lists selected new formulations or indications for previously approved drugs. Note: An addendum on cardiovascular safety of CGRP antagonists has been added to this issue - see the Addendum after the Test Questions page.
$10.00

OR

Subscribe and Save. Get access to this course PLUS the Rx Resource Library!

Explore Our Subscription Options

Course Information

Target Audience

Nurse Practitioner

Author
James Chan
PharmD, PhD
Knowledge Level

General Overview

This activity will apply to a broad range of learning needs/pharmacy settings. It may include common disease state/therapy overivews and/or general pharmacy needs such as medication errors, immunizations, or law topics.

Learning Objectives

  • For each of the drugs reviewed:
  • List the FDA approved indication(s), state the recommended dose(s), and discuss the evidence supporting the drug’s approval and potential role(s) in therapy.
  • Describe significant side effects and drug interactions.
  • Provide 2-3 patient counseling tips.
  • For drugs listed in Tables 2 and 3:
  • List the generic/brand names, dosage form(s), FDA approved indication(s), and major safety concerns.

Course Accreditation

  • Activity Type:
    Knowledge
  • CE Broker
    878482
  • Universal Activity Number:
    Nurse Practitioner : 0798-0000-21-208-H01
PharmCon is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

PharmCon, Inc. is an approved course provider for continuing education for nurses by the Florida Board of Nursing. PharmCon is also recognized by the California Board of Nursing as a provider of nursing programs.

In order to obtain a Statement of Credit, attendees must answer poll questions where presented and complete a program evaluation. Attendees may immediately print their Statement of Credit or leave them stored on the website.

Technology Requirements

  • Hardware Requirements
    Standard Windows/Mac System
    iPad or iPhone
    Minimum screen resolution: 1024x768
    Speakers or headphones
  • Software Requirements
    Standard Windows/Mac System
    iPad or iPhone
    Minimum screen resolution: 1024x768
    Speakers or headphones
  • Network Requirements
    Broadband Internet Connection:
    T1, Hi-speed DSL or Cable
    4G cellular connection
Computer sharing is NOT permitted due to accreditation guidelines on activity monitoring. Credit is earned by one user per device.